Publications by authors named "Satoshi Itano"

Claim this Profile
A
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.
Takeshi Hatanaka, Shigeo Shimose, Takanori Ito, Joji Tani, Tetsu Tomonari, Satoshi Itano

Hepatol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study.
Masatsugu Ishii, Osamu Itano, Hideki Iwamoto, Yuko Takami, Naomi Okada, Satoshi Itano

PLoS One· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.
Takanori Ito, Shigeo Shimose, Joji Tani, Tetsu Tomonari, Issei Saeki, Satoshi Itano

Hepatol Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Issei Saeki, Shigeo Shimose, Tetsu Tomonari, Takanori Ito, Joji Tani, Satoshi Itano

PLoS One· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shigeo Shimose, Issei Saeki, Tetsu Tomonari, Takanori Ito, Joji Tani, Satoshi Itano

Oncol Lett· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study.
Tomoya Sano, Keisuke Amano, Tatsuya Ide, Hiroshi Isoda, Yuichi Honma, Satoshi Itano

Hepatol Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Shigeo Shimose, Hideki Iwamoto, Tomotake Shirono, Masatoshi Tanaka, Takashi Niizeki, Satoshi Itano

Cancer Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Shigeo Shimose, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Takaaki Tanaka, Satoshi Itano

Sci Rep· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
Shigeo Shimose, Hideki Iwamoto, Masatoshi Tanaka, Takashi Niizeki, Masahiko Kajiwara, Satoshi Itano

Cancers (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study.
Masatsugu Ishii, Osamu Itano, Hideki Iwamoto, Taizo Hibi, Satoshi Itano

Oncology· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Masatsugu Ishii, Osamu Itano, Jun Morinaga, Hirofumi Shirakawa, Satoshi Itano

PLoS One· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and safety of a novel indwelling catheter system via the femoral artery for intermittent transarterial therapy for treating malignant liver tumors.
Hideki Iwamoto, Satoshi Itano, Osamu Itano, Masatsugu Ishii, Takashi Niizeki

Jpn J Radiol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shigeo Shimose, Atsushi Hiraoka, Masahito Nakano, Hideki Iwamoto, Masatoshi Tanaka, Satoshi Itano

Cancer Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
Hideki Iwamoto, Shigeo Shimose, Yu Noda, Tomotake Shirono, Takashi Niizeki, Satoshi Itano

Cancers (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.
Hideki Iwamoto, Takashi Niizeki, Hiroaki Nagamatsu, Kazuomi Ueshima, Takako Nomura, Satoshi Itano

Cancers (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with advanced hepatic fibrosis in patients with various internal diseases: A multicenter community-based survey.
Takumi Kawaguchi, Tetsuaki Inokuchi, Tomoki Honma, Satoshi Itano, Eiji Kawasaki

Hepatol Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent transcatheter therapy through a new indwelling catheter system for patients with hepatocellular carcinoma.
Osamu Itano, Satoshi Itano, Hiroaki Nagamatsu, Rina Tsutsui, Akihiro Deguchi

Jpn J Radiol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection.
Shuji Sumie, Takumi Kawaguchi, Mina Komuta, Ryoko Kuromatsu, Satoshi Itano

Oncol Rep· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperplastic nodular hepatic lesions following end-to-side portacaval shunting in childhood.
Nobuyoshi Fukushima, Ryoko Kuromatsu, Daiji Uchiyama, Satoshi Itano, Akio Takata

Intern Med· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporary indwelling catheter system via the left brachial artery: evaluation in 83 patients with hepatic tumors.
Sakae Nagaoka, Satoshi Itano, Hiroaki Nagamatsu, Junji Akiyoshi, Junichi Kurogi

AJR Am J Roentgenol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Appearance-specific satiety increases appetite and quality of life in patients with metastatic liver tumor: a case report.
Takumi Kawaguchi, Eitaro Taniguchi, Minoru Itou, Jyunji Akiyoshi, Satoshi Itano

Kurume Med J· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings.
Sakae Nagaoka, Satoshi Itano, Masatoshi Ishibashi, Takuji Torimura, Kenkichi Baba

Liver Int· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach.
Yasuyuki Ohtawa, Yoshio Naomoto, Yasuhiro Shirakawa, Munenori Takaoka, Toshihiro Murata, Satoshi Itano

Hum Pathol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
Hiroaki Nagamatsu, Satoshi Itano, Sakae Nagaoka, Junji Akiyoshi, Satoru Matsugaki

Am J Gastroenterol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC.
Hiroaki Nagamatsu, Ryukichi Kumashiro, Satoshi Itano, Satoru Matsugaki, Michio Sata

Hepatol Res· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis